Progress and novel strategies in vaccine development and treatment of anthrax

Immunological Reviews

Volumn 239, Issue 1, 2011, Pages 221-236

  Chitlaru, Theodor ^a   Altboum, Zeev ^a   Reuveny, Shaul ^a   Shafferman, Avigdor ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Bacillus anthracis; Immunogenic proteins; Postexposure prophylaxis; Protection correlates; Protective antigen; Reverse vaccinology

Indexed keywords

ACELLULAR VACCINE; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; ANTHRAX VACCINE; ANTIBODY; BACILLUS ANTHRACIS PROTECTIVE ANTIGEN; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; CIA 07; CIPROFLOXACIN; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; IMMUNOLOGICAL ADJUVANT; LIVE VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; OFLOXACIN; POLYCLONAL ANTIBODY; POLYGLUTAMIC ACID; RECOMBINANT VACCINE; STERNE LIKE LIVE VACCINE; SUBUNIT VACCINE; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRULENCE FACTOR;

ACTIVE IMMUNIZATION; ANTHRAX; ANTIBIOTIC THERAPY; ANTIGENICITY; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BIOINFORMATICS; BIOLOGICAL WARFARE; CELLULAR IMMUNITY; CONTROLLED RELEASE FORMULATION; DNA IMMUNIZATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INNATE IMMUNITY; LOW DRUG DOSE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEOMICS;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BIOLOGICAL WARFARE; DISEASE MODELS, ANIMAL; GUINEA PIGS; HUMANS; MICE; RABBITS; RATS; SPORES, BACTERIAL; VACCINES, DNA;

EID: 78650563014     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2010.00969.x     Document Type: Article

References (141)

1. Metcalfe N. The history of woolsorters' disease: a Yorkshire beginning with an international future? Occup Med 2004;54:489-493.
2. Carter KC. Koch's postulates in relation to the work of Jacob Henle and Edwin Klebs. Med Hist 1985;29:353-374.
3. Pasteur L. Classics of biology and medicine. Summary report of the experiments conducted at Pouilly-le-Fort, near Melun, on the anthrax vaccination. Translation of the original 1881 article. Yale J of Biol and Med 2002;75:59-62.
4. Driks A. The Bacillus anthracis spore. Mol Aspects Med 2009;30:368-373.
5. Mock M, Fouet A. Anthrax. Annu Rev Microbiol 2001;55:647-671.
6. Friedlander A, Welkos S, Ivins BE. Anthrax Vaccines. In: Koehler T ed. Anthrax. Netherlands: Springer Verlag, Curr Top Microbiol Immunol 2002;71:33-60.
7. Baillie L, Read T. Bacillus anthracis, a bug with attitude. Curr Opin Microbiol 2001;4:78-81.
8. Turnbull PCB. Introduction: anthrax history, disease and ecology. In: Koehler T ed. Anthrax. Curr Top Microbiol Immunol 2002;271:34-60. Springer-Verlag, Berlin.
9. Zilinkas RA. Iraq's Biological Weapons. The past as future? JAMA 1997;278:418-424.
10. Keim P, Smith KL, Keys C, Takahashi H, Kurata T, Kaufmann A. Molecular investigation of the Aum Shinrikyo anthrax release in Kameido, Japan. J Clin Microbiol 2001;39:4566-4567.
11. Blendon RJ, Benson JM, Des Roches CM, Pollard WE, Parvanta C, Herrmann MJ. The impact of anthrax attacks on the American public. Med Gen Med 2002;4:1.
12. Baillie L. Is new better than old? The development of human vaccines for anthrax. Hum Vaccin 2009;5:806-816.
13. Vilas-Boas GT, Peruca APS, Arantes OMN. Biology and taxonomy of Bacillus cereus, Bacillus anthracis, and Bacillus thuringiensis. Can J Microbiol 2007;53:673-687.
14. Rasko DA, Alther MR, Han CS, Ravel J. Genomics of the Bacillus cereus group of organisms. FEMS Microbiol Rev 2005;29:303-329.
15. Hoffmaster AR, et al. Identification of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation anthrax. Proc Natl Acad Sci USA 2004;101:8449-8454.
16. Bradley K, Mogridge J, Mourez M, Collier B, Young J. Identification of the cellular receptor for anthrax toxin. Nature 2001;414:225-229.
17. Collier RJ. Membrane translocation by anthrax toxin. Mol Aspects Med 2009;30:413-422.
18. Klimpel KR, Arora N, Leppla SH. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol Microbiol 1994;13:1093-1100.
19. Leppla S. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci USA 1982;79:3162-3166.
20. Lacy TM, Collier RJ. Structure and Function of Anthrax toxin. In: Koehler T ed. Anthrax. Netherland: Springer Verlag, Curr Top Microbiol Immunol 2002;271:62-85.
21. Maldonado-Arocho FJ, Averette-Mirrashidi KM, Bradley KA. Anthrax Toxin. In: Proft T ed. Microbial Toxins-Current Research and Future Trend. Norfolk, UK: Caister Academic Press, 2009:41-79.
22. Green BD, Battisti L, Koehler TM, Thorne CB, Ivins BE. Demonstration of a capsule plasmid in Bacillus anthracis. Infect Immmun 1985;49:291-297.
23. Leppla S. The bifactorial B. anthracis lethal and oedema toxins. In: Alouf JE, Freer JH eds. Comprehensive Sourcebook of Bacterial Protein Toxin. London, UK: Academic Press, 1999:243-263.
24. Koehler TM. Bacillus anthracis genetics and virulence gene regulation. In: Koehler T ed. Anthrax. Netherlands: Springer Verlag. Curr Top Microbiol Immunol 2002;271:144-164.
25. Wilson AC, Soyer M, Hoch JA, Perego M. The bicarbonate transporter is essential for Bacillus anthracis lethality. PLoS Pathog 2008;4:e1000210.
26. Moayeri M, Leppla SH. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol Aspects Med 2009;30:439-455.
27. Mignot T, Mock M, Fouet A. A plasmid-encoded regulator couples the synthesis of toxins and surface structures in Bacillus anthracis. Mol Microbiol 2003;47:917-927.
28. Bourgogne A, Drysdale M, Hilsenbeck SH, Peterson SN, Koehler TM. Global effects of virulence gene regulators in Bacillus anthracis strain with both virulence plasmids. Infect Immun 2003;71:2736-2743.
29. 2-dependent cross-talk mechanisms modulate extracellular proteolytic activities. J Bacteriol 2006;188:3551-3571.
30. Koehler TM. Bacillus anthracis physiology and genetics. Mol Aspects Med 2009;30:386-396.
31. Perego M, Hoch JA. Commingling regulatory systems following acquisition of virulence plasmids by Bacillus anthracis. Trends Microbiol 2008;16:215-221.
32. Fouet A, Mock M. Regulatory networks for virulence and persistence of Bacillus anthracis. Curr Opin Microbiol 2006;9:160-166.
33. Kukreja R, Singh BR. Botulinum neurotoxins-structure and mechanism of action. In: Proft T ed. Microbial Toxins-Current Research and Future Trend. Norfolk, UK: Caister Academic Press, 2009:15-40.
34. 5 toxin family. In: Proft T ed. Microbial Toxins-Current Research and Future Trend. Norfolk, UK: Caister Academic Press, 2009:81-89.
35. Fellows PF, et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001;19:3241-3247.
36. Brossier F, Levy M, Mock M. Anthrax spores make an essential contribution to vaccine efficacy. Infect Immunol 2002;70:661-664.
37. Cendrowski S, MacArthur W, Hanna P. Bacillus anthracis requires siderophore biosynthesis for growth in macrophages and mouse virulence. Molec Microbiol 2004;51:407-417.
38. Gat O, et al. The solute-binding component of a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence determinant. Mol Microbiol 2005;58:533-551.
39. Gat O, et al. Characterization of Bacillus anthracis iron-regulated surface determinant (Isd) proteins containing NEAT domains. Mol Microbiol 2008;70:983-999.
40. Fisher N, Shetron-Rama L, Herring-Palmer A, Heffernan B, Bergman N, Hanna P. The dltABCD operon of Bacillus anthracis Sterne is required for virulence and resistance to peptide, enzymatic, and cellular mediators of innate immunity. J Bacteriol 2006;188:1301-1309.
41. Gossens PL. Animal models of human anthrax: the quest for the holy grail. Mol Aspects Med 2009;30:467-480.
42. Hambleton P, Carman JA, Melling J. Anthrax: the disease in relation to vaccines. Vaccine 1984;2:125-132.
43. Belcome RE, Sullivan SE, Zeller R, Barker AP, Collier RJ, Chan J. Anthrax lethal toxin induces cell death-independent permeability in zebrafish vasculature. Proc Natl Acad Sci USA 2008;105:2439-2444.
44. Saile E, Koehler TM. Bacillus anthracis multiplication, persistence, and genetic exchange in the rhizosphere of grass plants. Appl Environ Microbiol 2006;72:3168-3174.
45. Newman ZL, et al. Susceptibility to anthrax lethal toxin-induced rat death is controlled by a single chromosome 10 locus. PLoS Pathog 2010;20:e1000906.
46. Fritz DL, et al. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest 1995;73:691-702.
47. Cybulski RJ, Sanz P, O'Brien AD. Anthrax vaccination strategies. Mol Aspects Med 2009;30:490-502.
48. Friedlander AM, Little SF. Advances in the development of next generation anthrax vaccines. Vaccine 2009;27:D28-D32.
49. Ivins BE, Welkos SL. Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol 1988;4:12-19.
50. Shlyakhov EN, Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine 1994;12:727-730.
51. Brachman PS, et al. Field evaluation of human anthrax vaccine. Am J Public Health 1962;52:632-645.
52. Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccine 2007;3:205-211.
53. Yan M, Roehrl MH, Basar E, Wang JY. Selection and evaluation of the immunogenicity of proective antigen mutants as anthrax vaccine candidates. Vaccine 2008;26:947-955.
54. Mendelson I, et al. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Vaccine 2005;23:5688-5697.
55. Joyce J, et al. Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-d-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J Biol Chem 2006;281:4831-4843.
56. Chabot DJ, Scorpio A, Tobery SA, Little SF, Norris SL, Friedlander AM. Anthrax capsule vaccine protects against experimental infection. Vaccine 2004;23:43-47.
57. Friedlander AM. The anthrax capsule: role in pathogenesis and target for vaccines and therapeutics. In: Shafferman A ed. The Challenge of Highly Pathogenic Microorganisms, Mechanisms of Virulence and Novel Medical Countermeasures. Netherlands: Springer, 2010:1-9.
58. Pezard C, Berche P, Mock M. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immunol 1991;59:3472-3477.
59. Pezard C, Weber M, Sirard JC, Berche P, Mock M. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect Immunol 1995;63:1369-1372.
60. Leppla S, Robbins J, Schneerson R, Shiloach J. Development of an improved vaccine for anthrax. J Clin Invest 2002;110:141-144.
61. Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR. Protection against lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 2001;69:4509-4515.
62. Schneerson R, et al. Poly-d-glutamic acid protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: A potential addition to the anthrax vaccine. Proc Natl Acad Sci USA 2003;100:8945-8950.
63. Rhie GE, Roehrl MH, Mourez M, Collier RJ, Mekalanos JJ, Wang JY. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc Natl Acad Sci USA 2003;100:10925-10930.
64. Kudva IT, Griffin RW, Garren JM, Calderwood SB, John M. Identification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation. Infect Immun 2005;73:5685-5696.
65. Whiting GC, Rijpkema S, Adams T, Corbel M. Characterization of adsorbed anthrax vaccine by two-dimensional gel electrophoresis. Vaccine 2004;22:4245-4251.
66. Reuveny S, et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immunol 2001;69:2888-2893.
67. Marcus H, Danieli R, Epstein E, Velan B, Shafferman A, Reuveny S. Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine. Infect Immunol 2004;72:3471-3477.
68. Cohen S, et al. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immunol 2000;68:4549-4558.
69. Singh Y, Ivins BE, Leppla SH. Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis. Infect Immun 1998;66:3447-3448.
70. Turnbull PCB. Anthrax vaccines: past, present and future. Vaccine 1991;9:533-539.
71. Tournier JN, Ulrich RG, Quesnel-Hellman A, Mohamadzadeh M, Stiles BG. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis. Expert Rev Anti Infect Ther 2009;7:219-236.
72. Weiss S, et al. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect Immun 2006;74:394-398.
73. Kobiler D, Gozes Y, Rosenberg H, Marcus D, Reuveny S, Altboum Z. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun 2002;70:544-560.
74. Little SF, Ivins BE, Fellows PF, Friedlander AM. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 1997;65:5171-5175.
75. Beedham RJ, Turnbull PC, Williamson ED. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 2001;19:4409-4416.
76. Hewetson JF, et al. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. Vaccine 2008;26:4262-4266.
77. Rosenfeld R, et al. Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal B. anthracis infection. PLoS ONE 2009;4:e6351.
78. Chitlaru T, Gat O, Gozlan Y, Grosfeld H, Inbar I, Shafferman A. Identification of in vivo expressed immunogenic proteins by serological proteome analysis of Bacillus anthracis secretome. Infect Immunol 2007;75:2841-2852.
79. Laffly E, et al. Selection of a Macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother 2005;49:3414-3420.
80. Gubbins MJ, et al. Production ad characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol Med Microbiol 2006;47:436-443.
81. Zarebski LM, et al. Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev Vaccines 2008;7:55-74.
82. Cote CK, Rossi CA, Kang AS, Morrow PR, Lee JS, Welkos SL. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb Pathog 2005;38:209-225.
83. Kang TJ, et al. Murine macrophages kill the vegetative form of Bacillus anthracis. Infect Immun 2005;73:7495-7501.
84. Hughes MA, et al. MyD88-Dependent signaling contributes to protection following B. anthracis spore challenge of mice: implications for toll-like receptor signaling. Infect Immun 2005;73:7535-7540.
85. Basu S, et al. Role of Bacillus anthracis spore structures in macrophage cytokine responses. Infect Immun 2007;75:2351-2358.
86. Weiss S, Levy H, Fisher M, Kobiler D, Altboum Z. Involvement of TLR2 in innate response to Bacillus anthracis infection. Innate Immun 2009;15:43-51.
87. Oscherwitz J, Yu F, Cease KB. A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen. Infect Immun 2009;77:5509-5518.
88. Pittman PR, et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 2002;20:1212-1420.
89. Ivins BE, et al. Efficacy of a standard human anthrax vaccine against bacillus anthracis aerosol spore challenge in rhesus monkeys. Salisbury Med Bull 1996;87(Suppl):125-126.
90. Aloni-Grinstein R, Gat O, Altboum Z, Velan B, Cohen S, Shafferman A. Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect Immun 2005;73:4043-4053.
91. Pittman PR, et al. Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid. Vaccine 2002;20:2107-2115.
92. Altboum Z, Gozes Y, Barnea A, Pass A, White M, Kobiler D. Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect Immun 2002;70:6231-6241.
93. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg 1956;54:28-36.
94. Jones WI, Beedman RJ, Turnbul PCB, Manchee RJ. Antibiotic prophylaxis for inhalational anthrax. Salisbury Med Bull 1996;87(Suppl):127-128.
95. Altboum Z, et al. The efficacy of antibiotic administration to cure intranasally infected guinea pigs with Bacillus anthracis spores. In: Shafferman A, Ordentlich A, Velan B eds. The Challenge of Highly Pathogenic Microorganisms, Mechanisms of Virulence and Novel Medical Countermeasure. Netherlands: Springer, 2010:287-293.
96. Friedlander AM, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993;167:1239-1243.
97. Vietri NJ, et al. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci USA 2006;103:7813-7816.
98. Kobiler D, et al. Protective antigen as a correlative marker for anthrax in animal models. Infect Immun 2006;74:5871-5876.
99. Franz DR. Preparedness for an anthrax attack. Mol Aspects Med 2009;30:503-510.
100. Casey LS, Porter J, Hulmes J, Sanford DC, Kirman I. Eti-204 anti-toxin monoclonal antibody treatment of active anthrax disease in rabbits. Bacillus-ACT 2009: The International Bacillus anthracis, B. cereus, and B. thuringiensis Conference; 2009 August 30-September 3. Santa Fe, New Mexico: American Society for Microbiology, 2009.
101. Basu S, Kang TJ, Whitford M, Meldorf MG, Lowy I, Cross AS. Mechanisms of an Anti-PA antibody (Valortim) that mediate protection against B. anthracis infection. Bacillus-ACT 2009: The International Bacillus anthracis, B. cereus, and B. thuringiensis Conference; 2009 August 30-September 3. Santa Fe, New Mexico: American Society for Microbiology, 2009.
102. Little SF, Knudson GB. Comparative efficacy of Bacillus anthracis live spore vaccineand protective antigen vaccine against anthrax in the guinea pig. Infect Immun 1986;52:509-512.
103. Bernard JP, Friedlander AM. Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen. Infect Immun 1999;67:562-567.
104. Ivins BE, Welkos SL, Knudson GB, Little SF. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect Immun 1990;58:303-308.
105. Coulson NM, Fulop M, Titball RW. Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL3261, affords protection against anthrax spore challenge. Vaccine 1994;12:395-1401.
106. Iacono-Connors LC, Welkos SL, Ivins BE, Dalrymple JM. Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect Immun 1991;59:1961-1965.
107. Ivins BE, Welkos SL. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis. Infect Immun 1986;54:537-542.
108. Welkos SL, Friedlander AM. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb Pathog 1988;5:127-139.
109. Gat O, et al. Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccines. Infect Immun 2003;71:801-813.
110. Ivins BE, Welkos SL, Little SF, Crumrine MH, Nelson GO. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect Immun 1992;60:662-666.
111. Coeshott CM, et al. PluronicR F127-based systemic vaccine delivery systems. Vaccine 2004;22:2396-2405.
112. Klinman DM, Xie H, Little SF, Currie D, Ivins BE. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 2004;22:2881-2886.
113. Kim SH, et al. Enhancement of the immune response s of mice to Bacillus anthracis protective antigen by CIA07 combined with Alum. Arch Pharm Res 2008;31:1385-1392.
114. McGowen AL, Hale LP, Shelburne CP, Abraham SN, Staats HF. The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine 2009;27:3544-3552.
115. Datta SK, et al. Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proc Natl Acad Sci USA 2010;107:10638-10643.
116. Whipple EC, et al. Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys. Mol Immunol 2007;44:377-388.
117. Kolla RV, et al. Complement C3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response. PLoS ONE 2007;10:e1044.
118. Brahmbhatt TN, et al. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Infect Immun 2007;75:5240-5247.
119. Read TD, et al. The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria. Nature 2003;423:81-86.
120. Okinaka R, et al. Sequence, assembly and analysis of pXO1 and pXO2. J Appl Microbiol 1999;87:261-262.
121. Bambini S, Rappuoli R. The use of genomics in microbial vaccine development. Drug Discov Today 2009;14:253-260.
122. Shafferman A, et al. Reverse Vaccinology in B. anthracis. In: Shafferman A, Ordentlich A, Velan B eds. The Challenge of Highly Pathogenic Microorganisms, Mechanisms of Virulence and Novel Medical Countermeasure. Netherlands: Springer, 2010:295-306.
123. Ariel N, et al. Search for potential vaccine candidate ORFs in the B. anthracis virulence plasmid pXO1-in silico and in vitro screening. Infect Immun 2002;70:6817-6827.
124. Ariel N, et al. Genome-based bioinformatic selection of chromosomal B. anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens. Infect Immun 2003;71:4563-4579.
125. Gat O, et al. Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen. Infect Immun 2006;74:3987-4001.
126. Gat O, Grosfeld H, Shafferman A. In vitro screen of bioinformatically selected Bacillus anthracis vaccine candidates by coupled transcription, translation and immunoprecipitation analysis. In: Grandi G ed. In Vitro transcription and Translation Protocols. Totowa, New Jersey, USA: Humana Press. Methods Mol Biol 2007;375:211-233.
127. Mesnage S, Tosi-Couture E, Mock M, Gounon P, Fouet A. Molecular characterization of the Bacillus anthracis main S-layer component: evidence that it is the major cell-associated antigen. Mol Microbiol 1997;23:1147-1155.
128. Fouet A, Mesnage S, Tosi-Couture E, Gounon P, Mock M. Bacillus anthracis surface: capsule and S-layer. J Appl Microbiol 1999;87:251-255.
129. Fouet A, Mesnage S. Bacillus anthracis cell envelope components. In: Koehler T ed. Anthrax. Netherlands: Springer Verlag, Curr Top Microbiol Immunol 2002;271:87-113.
130. Fouet A. The surface of Bacillus anthracis. Mol Aspects Med 2009;30:374-385.
131. Mignot T, Mesnage S, Couture-Tosi E, Mock M, Fouet A. Developmental switch of S-layer protein synthesis in B. anthracis. Molec Microbiol 2002;43:1615-1627.
132. Chitlaru T, et al. Identification of chromosomally encoded membranal polypeptides of Bacillus anthracis by a proteomic analysis: prevalence of proteins containing S-layer homology domains. Proteomics 2004;4:677-691.
133. Chitlaru T, Shafferman A. Proteomic analysis of B. anthracis. Future Microbiol 2009;4:983-998.
134. Antelmann H, et al. The extracellular and cytoplasmic proteomes of the non-virulent Bacillus anthracis strain UM23C1-2. Proteomics 2005;5:3684-3695.
135. Gohar M, Gilois N, Graveline R, Garreau C, Sanchis V, Lereclus D. A comparative study of B. cereus, B. thuringiensis and B. anthracis extracellular proteomes. Proteomics 2005;5:3696-3711.
136. Lamonica JM, et al. Comparative secretome analyses of three Bacillus anthracis strains with variant plasmid contents. Infect Immunol 2005;73:3646-3658.
137. Walz A, et al. Bacillus anthracis secretome time course under host-simulated conditions and identification of immunogenic proteins. Proteome Sci 2007;5:11-21.
138. 2-Moldulation and expression during infection of extracellular proteases. In: Shafferman A, Ordentlich A, Velan B eds. The Challenge of Highly Pathogenic Microorganisms, Mechanisms of Virulence and Novel Medical Countermeasure. Netherlands: Springer, 2010:11-22.
139. Sela-Abramovich S, Chitlaru T, Gat O, Grosfeld H, Cohen O, Shafferman A. Novel and unique diagnostic biomarkers for Bacillus anthracis infection. Appl Environ Microbiol 2009;75:6157-6167.
140. Kern JW, Schneewind O. BslA, a pXO1-encoded adhesin of Bacillus anthracis. Mol Microbiol 2008;68:504-515.
141. Davison S, Couture-Tosi E, Candela T, Mock M, Fouet A. Identification of the Bacillus anthracisγ-Phage receptor. J Bacteriol 2005;187:6742-6749.